Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

NCT00002778 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

40

Enrollment

OTHER

Sponsor class

Stopped subject accrual and data analysis is completed.

Conditions

Leukemia

Interventions

BIOLOGICAL: sargramostim
BIOLOGICAL: therapeutic allogeneic lymphocytes
PROCEDURE: allogeneic bone marrow transplantation
PROCEDURE: in vitro-treated bone marrow transplantation

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]